Proteome Sciences (LON:PRM) Shares Up 34.6% – Should You Buy?

Proteome Sciences plc (LON:PRM) shot up 34.6% during mid-day trading on Wednesday . The stock traded as high as GBX 2 and last traded at GBX 1.89. 782,692 shares traded hands during mid-day trading, an increase of 87% from the average session volume of 417,714 shares. The stock had previously closed at GBX 1.40.

Proteome Sciences Price Performance

The business has a 50-day simple moving average of GBX 1.61 and a 200 day simple moving average of GBX 1.87. The firm has a market cap of £5.96 million, a P/E ratio of -1.63 and a beta of 0.15. The company has a debt-to-equity ratio of -165.46, a quick ratio of 0.37 and a current ratio of 0.13.

Proteome Sciences (LON:PRM) last released its quarterly earnings data on Wednesday, April 15th. The company reported GBX (1.04) earnings per share for the quarter. Proteome Sciences had a positive return on equity of 33.80% and a negative net margin of 81.50%.The business had revenue of GBX 376 million during the quarter.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.